Bellicum Logo.jpg
Bellicum Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Operational Update
November 06, 2019 16:15 ET | Bellicum Pharmaceuticals, Inc.
Raised gross proceeds of $69.6 million from public offering and private placement option fee Narrowed strategic focus to core GoCAR-T® cell therapy programs Cost saving initiatives underway to...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Announces Presentation on CAR-NK Cell Program at SITC 2019
October 31, 2019 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an...
Bellicum Logo.jpg
Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update
October 30, 2019 07:30 ET | Bellicum Pharmaceuticals, Inc.
- Management to host webcast and conference call on Wednesday, November 6, 2019 at 5 p.m. ET / 2 p.m. PT -   HOUSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM),...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2019 16:07 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Logo.jpg
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 30, 2019 16:08 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Logo.jpg
Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September
August 28, 2019 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc.
February 12, 2018 15:17 ET | Federman & Sherwood
OKLAHOMA CITY, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Federman & Sherwood announces that on February 6, 2018, a class action lawsuit was filed in the United States District Court for the Southern...